Lytix Biopharma ASA (OSL:LYTIX)
Norway
· Delayed Price · Currency is NOK | Market Cap | 792.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.98M |
| Shares Out | 76.90M |
| EPS (ttm) | -0.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,567 |
| Average Volume | 56,856 |
| Open | 10.55 |
| Previous Close | 10.30 |
| Day's Range | 10.10 - 10.55 |
| 52-Week Range | 5.00 - 11.90 |
| Beta | -0.49 |
| RSI | 51.92 |
| Earnings Date | May 21, 2026 |
About Lytix Biopharma ASA
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as he... [Read more]
Financial Performance
Financial StatementsNews
Lytix Biopharma ASA Earnings Call Transcript: Q4 2025
Strong clinical data and a NOK 77 million capital raise have positioned the company for pivotal studies and partnerships, with a cash runway into 2027. Interim results in key trials are promising, and multiple assets are validated as multi-billion-dollar opportunities.
Lytix Biopharma ASA Earnings Call Transcript: Q3 2025
Strong clinical data for ruxotemitide in BCC and melanoma support advancement toward commercialization, with stable financials and sufficient funding through 2026. Phase III studies are planned, with partnerships considered for financing.
Lytix Biopharma ASA Earnings Call Transcript: Q2 2025
Q2 saw a sharply reduced net loss due to a one-off accrual reversal, with a strong cash position extending into 2026. Key milestones ahead include interim NeoLIPA data in November and phase III plans for LTX-315 in BCC, while LTX-401 advances preclinically.
Lytix Biopharma ASA Earnings Call Transcript: Q1 2025
Strong phase II results for LTX-315 in basal cell carcinoma and melanoma, with a robust cash position supporting operations into 2026. Key milestones include interim NeoLIPA data in Q3 2025 and a phase III update for LTX-315 mid-2025.
Lytix Biopharma ASA Earnings Call Transcript: Q4 2024
Strong phase II results for LTX-315 in BCC and ongoing melanoma studies highlight robust clinical progress, supported by a NOK 111 million capital raise and a solid financial runway into 2026. Strategic focus remains on advancing clinical programs and commercialization.
Lytix Biopharma ASA Earnings Call Transcript: Q3 2024
Strong phase II results for LTX-315 in melanoma and basal cell carcinoma highlight robust clinical progress, with financial stability supported by a recent share offering and milestone-driven partnerships. Cash runway extends into 2025, and multiple studies and regulatory milestones are on track.
Lytix Biopharma ASA Earnings Call Transcript: Q2 2024
Strong clinical progress with LTX-315 in BCC and melanoma, including 86% tumor reduction in BCC and durable disease control in late-stage melanoma. Operating expenses declined, cash runway extended into 2025, and a new LTX-401 formulation shows promise.
Lytix Biopharma ASA Transcript: Study Update
Phase 2 results for LTX-315 in BCC showed an 86% average tumor reduction and complete elimination in over half of patients, with no serious side effects. LTX-315 is positioned as a potential first-line, less invasive treatment, with significant commercial and clinical milestones ahead.